Compare Enveric Biosciences Inc (ENVB) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Marsh & McLennan Companies, Inc. trades at $176.51 (market cap $82.87B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 12387.1× Enveric Biosciences Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.28% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| ENVB | MRSH | |
|---|---|---|
Market Cap | $6.69M | $82.87B |
Volume | 41,141 | 2,731,994 |
Sector | Health | Financials |
52-Week High | $10.80 | $207.02 |
52-Week Low | $1.27 | $157.32 |
Typical Hold Time | 14 Days | 109 Days |
Enterprise Value | -$1.60M | $103.55B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Marsh (MRSH) trades at $176.67, up 2.86% today, with a bullish technical signal and strong fundamentals including a 14.24% net income margin and consistent earnings beats. The recent acquisition of Accel Holdings, completed October 2, 2026, enhances its global advisory services. Revenue grew to $26.98B in 2025, and cash flow from operations remains robust at $5.29B, supporting a stable financial position.
The stock offers upside to the consensus price target of $202.71, but risks include high debt levels and competitive pressures. Analyst sentiment is mixed with a 'Hold' consensus, while technical indicators show overbought conditions near resistance at $177. Long-term growth depends on integration of acquisitions and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
